Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nao Yoshida-Sakai"'
Autor:
Taichi Matsumoto, Yuichi Murakami, Nao Yoshida-Sakai, Daisuke Katsuchi, Kuon Kanazawa, Takashi Okamura, Yutaka Imamura, Mayumi Ono, Michihiko Kuwano
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 9, p 4583 (2024)
5-azacytidine (AZA), a representative DNA-demethylating drug, has been widely used to treat myelodysplastic syndromes (MDS). However, it remains unclear whether AZA’s DNA demethylation of any specific gene is correlated with clinical responses to A
Externí odkaz:
https://doaj.org/article/69aad63d87084e21b0be69453b9e7a38
Autor:
Yuki Kurahashi, Tatsuro Watanabe, Yuta Yamamoto, Hiroshi Ureshino, Kazuharu Kamachi, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Satoshi Yamashita, Naoko Hattori, Hideaki Nakamura, Atsushi Kawaguchi, Toshikazu Ushijima, Eisaburo Sueoka, Shinya Kimura
Publikováno v:
Blood Advances. 7:1545-1559
Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4+ T cells caused by human T-cell lymphotropic virus type 1 (HTLV-1)–induced T-cell transformation. After infection with HTLV-1, it takes several decades for HTLV-1 carriers to develo
Autor:
Shinya Kimura, Yuki Kurahashi, Yuta Yamamoto, Toshimi Hoshiko, Kazunori Kawasoe, Yuki Fukuda-Kurahashi, Nao Yoshida-Sakai, Tatsuro Watanabe, Hiroshi Ureshino, Kazuharu Kamachi
Figure S3. BCL2 and BCL-xL levels in HL60 and KG1a following Vehicle (Cont), 1.0 mM of OR21 (OR1), 0.1 mM (HL60) or 0.5 mM (KG1a) of venetoclax and OR21 and venetoclax (OR+Ven) combination treatment. n.s. indicated not significant.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67fa96a809468d3bee10f550a5fa6b1e
https://doi.org/10.1158/2767-9764.22546530.v1
https://doi.org/10.1158/2767-9764.22546530.v1
Autor:
Shinya Kimura, Yuki Kurahashi, Yuta Yamamoto, Toshimi Hoshiko, Kazunori Kawasoe, Yuki Fukuda-Kurahashi, Nao Yoshida-Sakai, Tatsuro Watanabe, Hiroshi Ureshino, Kazuharu Kamachi
The transcripts per million (TPM) values of six downregulated genes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b7d0549274490b8afcf877178e706b7
https://doi.org/10.1158/2767-9764.22546503
https://doi.org/10.1158/2767-9764.22546503
Autor:
Shinya Kimura, Yuki Kurahashi, Yuta Yamamoto, Toshimi Hoshiko, Kazunori Kawasoe, Yuki Fukuda-Kurahashi, Nao Yoshida-Sakai, Tatsuro Watanabe, Hiroshi Ureshino, Kazuharu Kamachi
The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2–selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::631669efca7134a0cb85a988eb9e7748
https://doi.org/10.1158/2767-9764.c.6551193
https://doi.org/10.1158/2767-9764.c.6551193
Autor:
Nao Yoshida‐Sakai, Tatsuro Watanabe, Yuta Yamamoto, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda‐Kurahashi, Shinya Kimura
Publikováno v:
International Journal of Cancer. 150:1184-1197
Autor:
Nao Yoshida-Sakai, Kensuke Oe, Yoshizo Kimura, Hiroshi Ureshino, Keita Nomiyama, Michitoshi Hashiguchi, Hiroto Jojima, Yutaka Imamura, Koichi Ohshima, Takashi Okamura
Publikováno v:
Annals of Hematology. 101:1383-1385
Autor:
Naoko Hattori, Nao Yoshida-Sakai, Yuta Yamamoto, Yoshihiro Hayashi, Shinya Kimura, Seiji Okada, Hiroshi Ureshino, Yuki Kurahashi, Toshikazu Ushijima, Hironori Harada, Yuki Fukuda-Kurahashi, Kazuharu Kamachi, Satoshi Yamashita, Tatsuro Watanabe, Kaoru Tohyama, Atsushi Kawaguchi
Publikováno v:
Molecular cancer therapeutics. 20(8)
DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or
Publikováno v:
Medicine. 100:e25867
Rationale Ecthyma gangrenosum (EG) is an uncommon cutaneous infection usually associated with Pseudomonas aeruginosa bacteremia in immunocompromised patients, particularly those with underlying malignant diseases. Despite its rarity, especially in im
Autor:
Yoshiro Hadano, Nao Yoshida-Sakai, Yutaka Imamura, Tomohiro Inoue, Hitoshi Koga, Hadano, Yoshiro, Yoshida-Sakai, Nao, Imamura, Yutaka, Inoue, Tomohiro, Koga, Hitoshi
Publikováno v:
Medicine; 5/7/2021, Vol. 100 Issue 18, p1-3, 3p